CAJ | 학술논문

继发性甲状旁腺功能亢进症(SHPT)是慢性肾脏病(CKD)常见的并发症。近年研究发现，新型的磷结合剂碳酸镧，能有效降低血清磷水平，并不引起继发骨损害和高钙血症，是一种相对较安全的磷结合剂，西那卡塞是被称为拟钙剂(calcimimetics)的新一类化合物中的第一个药物，能激活甲状旁腺中的钙受体，从而降低甲状旁腺素的分泌。尤其适用于慢性肾衰竭患者顽固性、继发性甲状旁腺功能亢进伴有高磷血症的短期治疗。
계발성갑상방선공능항진증(SHPT)시만성신장병(CKD)상견적병발증。근년연구발현，신형적린결합제탄산란，능유효강저혈청린수평，병불인기계발골손해화고개혈증，시일충상대교안전적린결합제，서나잡새시피칭위의개제(calcimimetics)적신일류화합물중적제일개약물，능격활갑상방선중적개수체，종이강저갑상방선소적분비。우기괄용우만성신쇠갈환자완고성、계발성갑상방선공능항진반유고린혈증적단기치료。
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). Recent studies have found that new phosphate binder lanthanum carbonate, can effectively reduce the level of serum phosphorus, do not cause secondary damage to the bone and hypercalcemia, are a relatively safe phosphate binders. Cinacalcet is known as the calcimimetic agent (calcimimetics) a new class of compounds in the first drug, can activate the parathyroid calcium receptor, thereby reducing the parathyroid hormone secretion. Especially for chronic renal failure patients with chronic renal failure, secondary Hyperthyroidism Accompanied by high levels of phosphorus in the short-term treatment.